Analysis of subgroups demonstrated that the survival benefit associated with adjuvant chemotherapy was consistent across categories, including gender, age under 59 years, stage I and stages II–III, smoking status, peripheral tumor location, TFF-1 positivity and negativity, CD56 positivity, and lobectomy. This evidence concerns the gene NCAM1 and neoplasm.